FDA Approves Oral AML Therapy for Elderly Patients Unfit for Intensive Chemo
Inqovi gains approval for newly diagnosed AML in patients 75+ or with comorbidities, offering a gentler oral treatment route.
Summary
The FDA has approved Inqovi — a fixed-dose oral combination of decitabine and cedazuridine — for adult patients newly diagnosed with acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that make standard intensive induction chemotherapy too risky. This marks a meaningful advance for a population that has historically had few safe treatment options. Decitabine is a hypomethylating agent that helps reactivate silenced tumor-suppressor genes, while cedazuridine inhibits the enzyme that normally breaks down oral decitabine, making effective blood levels achievable without IV administration. The oral formulation reduces hospital burden and improves convenience for frail or elderly patients. This approval expands the already approved use of Inqovi in myelodysplastic syndromes and adds a critical option in AML for those who cannot tolerate aggressive therapy.
Detailed Summary
Acute myeloid leukemia is an aggressive blood cancer with poor prognosis, and the challenge intensifies in elderly or medically fragile patients who cannot withstand standard intensive induction chemotherapy. Until now, treatment options for this subset were limited and often inadequate. The FDA's approval of Inqovi for newly diagnosed AML in patients aged 75 or older, or those with disqualifying comorbidities, addresses a genuine unmet clinical need.
Inqovi is a fixed-dose oral tablet combining decitabine, a DNA hypomethylating agent, with cedazuridine, a cytidine deaminase inhibitor. Cedazuridine's role is pharmacological: it blocks the gut and liver enzyme that ordinarily degrades oral decitabine too rapidly for therapeutic effect, enabling reliable systemic exposure comparable to intravenous administration.
This approval follows the drug's established use in myelodysplastic syndromes and chronic myelomonocytic leukemia, extending the hypomethylating strategy into the AML setting. The combination is now approved for use alongside azacitidine, another hypomethylating agent, forming a dual-mechanism oral regimen intended to provide deeper epigenetic reprogramming of leukemic cells.
For clinicians, the significance is practical: oral administration means patients can be treated in outpatient or home settings, reducing hospitalization risk, infection exposure, and caregiver burden — all especially important in elderly populations. This aligns with a broader oncology trend toward outpatient-compatible regimens for fit-but-fragile patients.
Caveats remain. Hypomethylating-based regimens in AML are not curative for most patients and median survival improvements, while meaningful, are modest. Clinicians should weigh response rates, quality of life, and patient goals carefully. The full clinical trial data supporting this specific AML indication warrants review as it becomes available in peer-reviewed publications.
Key Findings
- FDA approved Inqovi (decitabine + cedazuridine) for newly diagnosed AML on May 13, 2026.
- Indicated for patients aged 75+ or those with comorbidities precluding intensive chemotherapy.
- Oral formulation achieves IV-equivalent decitabine exposure via cedazuridine enzyme inhibition.
- Used in combination with azacitidine for dual hypomethylating agent coverage.
- Expands Inqovi's prior approvals in MDS and CMML into the AML setting.
Methodology
This is an FDA approval notification rather than a primary clinical trial publication. The approval is based on clinical trial evidence submitted to the FDA, the details of which are not available in this abstract. Full trial design and efficacy data should be sought from the FDA label and forthcoming peer-reviewed publications.
Study Limitations
This summary is based on the abstract and approval notification only — full trial data, survival endpoints, and safety profiles from the supporting clinical studies are not yet reviewed here. The abstract does not specify which clinical trial(s) underpinned the approval, limiting assessment of methodology and effect size. Clinicians should consult the FDA label and primary trial publications before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.